Earnings summaries and quarterly performance for RIGEL PHARMACEUTICALS.
Executive leadership at RIGEL PHARMACEUTICALS.
Raul Rodriguez
Detailed
Chief Executive Officer
CEO
DS
David Santos
Detailed
Executive Vice President and Chief Commercial Officer
DS
Dean Schorno
Detailed
Executive Vice President and Chief Financial Officer
LR
Lisa Rojkjaer
Detailed
Executive Vice President and Chief Medical Officer
RF
Raymond Furey
Detailed
Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary
Board of directors at RIGEL PHARMACEUTICALS.
Research analysts who have asked questions during RIGEL PHARMACEUTICALS earnings calls.
Joseph Pantginis
H.C. Wainwright & Co.
4 questions for RIGL
Also covers: ARMP, BCDA, BLRX +15 more
YN
Yigal Nochomovitz
Citigroup Inc.
3 questions for RIGL
Also covers: ALDX, APLS, ARCT +22 more
Farzin Haque
Jefferies
2 questions for RIGL
Also covers: ABEO, ARWR, AUPH +3 more
KP
Kalpit Patel
B. Riley Securities
2 questions for RIGL
Also covers: DERM, FBRX, GERN +4 more
Amin Makarem
Jefferies
1 question for RIGL
Also covers: ABEO, CELC, CMPX
Ayan Hussein
Cantor Fitzgerald
1 question for RIGL
Also covers: XFOR
Kristen Kluska
Cantor Fitzgerald
1 question for RIGL
Also covers: ABEO, ADMA, AQST +24 more
Recent press releases and 8-K filings for RIGL.
Rigel Pharmaceuticals Reports Strong 2025 Performance and Provides 2026 Guidance
RIGL
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Rigel Pharmaceuticals achieved profitability in Q3 2024 and has since generated $100 million in cash, doubling its cash position to $154 million in calendar year 2025.
- The company reported substantial commercial growth in 2025, with sales increasing by almost $90 million and Q4 2025 showing 41% growth year-over-year.
- For 2026, Rigel projects total revenue of $275 million-$290 million, comprising $255 million-$265 million in product revenue and $20 million-$25 million in contract revenue, expecting to remain net cash positive.
- Commercial products demonstrated strong performance, with TAVALISSE reaching $45 million in sales in Q4 2025 with 47% growth, and GAVRETO and REZLIDHIA each growing to over $10 million per quarter.
- Rigel is advancing its pipeline, notably with R289 (IRAK1 and 4 inhibitor) for low-risk MDS, which represents a potential multi-hundred million to billion-dollar opportunity, with a registrational study anticipated in 2027.
1 day ago
Rigel Pharmaceuticals Reports Strong 2025 Performance and Provides 2026 Guidance
RIGL
Revenue Acceleration/Inflection
Guidance Update
New Projects/Investments
- Rigel Pharmaceuticals achieved profitability in Q3 2024 and has since generated $100 million in cash.
- The company reported a "stellar year" in 2025, with almost $90 million in sales growth and 41% growth in Q4 2025 over the prior year's Q4.
- Rigel's cash position doubled to $154 million in calendar year 2025.
- For 2026, the company provided guidance of $275-$290 million in total revenue, comprising $255-$265 million in product revenue and $20-$25 million in contract revenue, and expects to be net cash positive.
- Key strategic objectives include growing the commercial business, in-licensing late-stage products for launch between 2026 and 2028, and advancing the R289 pipeline asset, which is a potential multi-hundred million to billion-dollar opportunity with a registrational study planned for 2027.
1 day ago
Rigel Pharmaceuticals Updates on Strategy, Financials, and Pipeline
RIGL
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Rigel Pharmaceuticals achieved profitability in Q3 2024 and has since generated $100 million in cash, increasing its cash position to $154 million in calendar year 2025.
- For 2026, the company projects total revenue between $275 million and $290 million, comprising $255 million to $265 million in product revenue and $20 million to $25 million in contract revenue, while maintaining a net cash positive position.
- The commercial business, featuring products like Tavalisse, Rezlidhia, and Gavreto, saw 35% growth from 2022 to a guided midpoint of $260 million for 2025, with the Inflation Reduction Act (IRA) contributing to Tavalisse's performance.
- The lead pipeline asset, R289, an IRAK1 and 4 inhibitor for low-risk Myelodysplastic Syndromes (MDS), demonstrated a 33% response rate in transfusion-dependent patients in its Phase 1b study, with a registrational study anticipated in 2027.
1 day ago
Rigel Pharmaceuticals Provides Q4 and Full-Year 2025 Preliminary Results and 2026 Outlook
RIGL
Earnings
Guidance Update
- Rigel reported preliminary Q4 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million, and preliminary full-year 2025 total revenue of $294.3 million with net product sales of $232.0 million.
- The company's cash, cash equivalents, and short-term investments were approximately $154.6 million as of December 31, 2025, significantly up from $77.3 million at the end of 2024.
- For 2026, Rigel anticipates total revenue of $275 to $290 million, including net product sales of $255 to $265 million, and expects to achieve positive net income for the full year.
- In clinical development, the Phase 1b study of R289 in lower-risk MDS showed red blood cell transfusion independence (RBC-TI) in 33% (6/18) of evaluable transfusion-dependent patients receiving doses of at least 500 mg QD, with preliminary data from the dose expansion phase expected by the end of 2026.
- The FDA approved a supplemental New Drug Application for GAVRETO to add a boxed warning regarding serious infections in December 2025.
3 days ago
Rigel Pharmaceuticals Provides Business Update and 2026 Outlook
RIGL
Earnings
Guidance Update
New Projects/Investments
- Rigel Pharmaceuticals reported preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million, and expects full-year 2025 total revenue of $294.3 million, with net product sales of $232.0 million.
- The company anticipates reporting cash, cash equivalents, and short-term investments of approximately $154.6 million as of December 31, 2025.
- For 2026, Rigel projects full-year total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million, and expects to achieve positive net income for the full year.
- The Phase 1b study of R289 in lower-risk MDS continues to show R289 is generally well tolerated, with red blood cell transfusion independence (RBC-TI) achieved by 33% (6/18) of evaluable transfusion dependent patients receiving doses ≥500 mg QD, and enrollment in the dose expansion phase is on track to complete in the second half of 2026.
3 days ago
Rigel Presents Updated Phase 1b Data for R289 in Lower-Risk MDS
RIGL
New Projects/Investments
Guidance Update
- Rigel Pharmaceuticals, Inc. presented updated data from its ongoing Phase 1b study evaluating R289 in patients with lower-risk myelodysplastic syndrome (MDS) at the 67th ASH Annual Meeting and Exposition on December 7, 2025.
- The study indicated that R289 was generally well tolerated, with preliminary efficacy observed in elderly, heavily pre-treated lower-risk MDS patients at doses of ≥500 mg QD.
- 33% (6/18) of evaluable transfusion-dependent patients receiving R289 doses ≥500 mg QD achieved red blood cell transfusion independence (RBC-TI), with a median duration of RBC-TI of 22.9 weeks.
- Enrollment in the dose escalation phase was completed in July 2025, and the dose expansion phase began in October 2025. Rigel anticipates selecting the recommended Phase 2 dose for future clinical studies in the second half of 2026.
Dec 10, 2025, 9:05 PM
Rigel Pharmaceuticals Reports Strong Product Sales Growth and Increased Revenue Guidance
RIGL
Revenue Acceleration/Inflection
Guidance Update
New Projects/Investments
- Rigel Pharmaceuticals reported strong U.S. net product sales growth of 65% year-over-year to $64.1 million in Q4 2025 and $166 million through Q3 2025.
- The company increased its total revenue guidance for 2025 to $285-$290 million, with net product sales guidance of $225-$230 million.
- Key product performance includes Tavalisse sales of $44.7 million with 70% year-over-year growth, Gavreto sales growing to over $11 million per quarter, and Rezlidhia showing 50% year-over-year growth.
- Rigel achieved net income of approximately $28 million through Q3 2025 and increased its cash balance by $60 million to $137 million.
- The company is advancing its pipeline, including the IRAK1/4 inhibitor program with an upcoming oral presentation at ASH and fast-track/orphan designation, and pursuing in-licensing opportunities for differentiated hematology/oncology assets.
Dec 3, 2025, 1:30 PM
Rigel Updates on Financial Performance, Product Growth, and Pipeline at Piper Sandler Conference
RIGL
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Rigel reported $166 million in total revenue through Q3 and $64 million in Q3 alone, achieving profitability in each of the first three quarters ,.
- The company increased its full-year total revenue guidance to $285-$290 million, with net product sales guidance of $225-$230 million.
- Key products demonstrated strong growth, including Tavalisse with 70% year-over-year growth to $44.7 million, Gavreto sales exceeding $11 million per quarter, and Rezlidhia growing 50% year-over-year.
- Rigel's IRAK1/4 inhibitor program for lower risk MDS has received Fast-Track and Orphan Designation from the FDA, with new data to be presented at ASH and the dose expansion phase underway.
- The company's cash balance increased by $60 million to $137 million, providing funding for pipeline opportunities.
Dec 3, 2025, 1:30 PM
Rigel Pharmaceuticals CFO Highlights Strong Commercial Growth and Pipeline Opportunities
RIGL
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Rigel Pharmaceuticals reported US net product sales of $64 million in Q3 and $166 million cumulatively through Q3, reflecting 65% year-over-year growth.
- The company has increased its full-year guidance for total revenue to $285 million-$290 million, with net product sales projected at $225 million-$230 million and collaboration revenues at $60 million, representing 55%-59% year-over-year growth.
- Rigel's commercial products, including TAVALISSE ($44.7 million) and GAVRETO (over $11 million), are experiencing significant growth, with TAVALISSE showing 70% year-over-year growth.
- The company is advancing its pipeline with an IRAK1/4 inhibitor program in lower-risk MDS, which will have an oral presentation at ASH, and strategic collaborations for olutasidenib in various IDH1 positive indications.
- Rigel maintains a strong financial position with a cash balance of $137 million and net income of approximately $28 million through Q3.
Dec 3, 2025, 1:30 PM
Rigel Pharmaceuticals Updates on Strong Commercial Growth, Profitability, and Pipeline Progress at Jefferies Conference
RIGL
Revenue Acceleration/Inflection
Guidance Update
New Projects/Investments
- Rigel Pharmaceuticals reported strong financial performance, achieving profitability in 2024 and through the first three quarters of 2025, generating $60 million in cash year-to-date.
- Net product sales for the last quarter reached $64 million, marking a 65% increase year-over-year, with significant contributions from TAVALISSE, REZLIDHIA, and GAVRETO.
- The company raised its full-year 2025 guidance, projecting total revenue between $285-$290 million and net product sales of $225-$230 million, while reaffirming its expectation for net income positive results.
- Rigel's pipeline includes R289, an IRAK1/4 inhibitor for low-risk MDS, with new data to be presented at the upcoming ASH meeting and a registration study targeted for 2027.
- The strategic focus involves continued commercial expansion, in-licensing additional late-stage hematology and oncology assets, and funding transformational pipeline programs with internally generated cash.
Nov 18, 2025, 10:00 AM
Quarterly earnings call transcripts for RIGEL PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more